Heart Biotech Trevena, Inc. Files for a $86 Million IPO

Published: Oct 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Trevena, Inc. (Nasdaq: TRVN) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86.25 million. The company plans to list on the Nasdaq Global Market under the ticker, "TRVN." The offering is being made via Barclays, Jefferies, Canaccord Genuity, JMP Securities, and Needham & Company.

Help employers find you! Check out all the jobs and post your resume.

Back to news